What is the role of PARP inhibitors in pancreatic cancer?

Ritika Halder; Rachna T Shroff

doi:10.1080/14737140.2020.1816174

What is the role of PARP inhibitors in pancreatic cancer?

Expert Rev Anticancer Ther. 2020 Nov;20(11):913-918. doi: 10.1080/14737140.2020.1816174. Epub 2020 Sep 11.

Authors

Ritika Halder¹, Rachna T Shroff^{2

3}

Affiliations

¹ Internal Medicine Residency Program, University of Arizona , Tucson, AZ, USA.
² Division of Hematology and Oncology, University of Arizona College of Medicine , Tucson, AZ, USA.
³ Section of GI Medical Oncology, University of Arizona Cancer Center , Tucson, AZ, USA.

PMID: 32865047
DOI: 10.1080/14737140.2020.1816174

No abstract available

Keywords: BRCA mutation; DNA damage response; PARP inhibitor; Pancreatic cancer; olaparib; pancreatic adenocarcinoma; polyadenosine diphosphate-ribose polymerase; rucaparib; targeted therapy; veliparib.

Publication types

Editorial

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / pathology
Humans
Molecular Targeted Therapy
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / pathology
Poly(ADP-ribose) Polymerase Inhibitors / administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
Survival Rate

Substances

Poly(ADP-ribose) Polymerase Inhibitors